Medline Inc. faced significant FDA violations related to manufacturing quality, including failure to investigate contamination and cleaning issues. The FDA issued a warning letter in May 2026, marking the second such action in two months. Following this, Medline's stock fell over 7%, and it dropped further by 12% after disappointing Q2 results and lowered full-year earnings guidance. Investors who suffered losses may have legal rights under federal securities laws.
Celldex Therapeutics received a Buy rating upgrade from H.C. Wainwright, with the price target raised to $64 from $42, following successful Phase 3 clinical trials of barzolvolimab. The drug showed rapid and lasting benefits for patients with a chron...
dLocal offers a unified payment gateway enabling global merchants to access over 60 emerging markets, fueling strong transaction volume and revenue growth. Although its take-rate has compressed to 0.71%, this is mainly due to merchant mix, volume tie...
Qualcomm introduced its Snapdragon 8 Elite Gen 6 chipsets, designed for high-end Android smartphones with enhanced on-device AI capabilities. Built using TSMC's 2-nanometer process, these chips target premium brands like Motorola, Xiaomi, and ZTE ami...
Simmons First National Corporation announced it will host an Investor Day on December 10, 2026, in New York City. The event will feature presentations by CEO Jay Brogdon, CFO Daniel Hobbs, and other executives discussing the company's strategic prior...
Quest Diagnostics announced it will release its third quarter 2026 financial results on October 22, 2026, before the market opens. The company will hold a conference call at 8:30 a.m. Eastern Time to discuss the results, accessible via phone and webc...
